FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology（2022）
摘要
The addition of trastuzumab/pertuzumab to perioperative FLOT significantly improved pCR and nodal negativity rates at the price of higher rates of diarrhea and leukopenia.
更多查看译文
关键词
2–positive resectable esophagogastric adenocarcinoma,epidermal growth factor receptor,flot/trastuzumab/pertuzumab perioperative therapy
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要